Taraasian Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-12-2024
- Paid Up Capital ₹ 1.00 M
as on 07-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -10.85%
(FY 2022)
- Profit -787.96%
(FY 2022)
- Ebitda -591.47%
(FY 2022)
- Net Worth -22.32%
(FY 2022)
- Total Assets -11.71%
(FY 2022)
About Taraasian Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Bhupendra Marliwar, Bhushan Marliwar, Bhraman Marliwar, and Eight other members serve as directors at the Company.
- CIN/LLPIN
U74999MH2017PTC297577
- Company No.
297577
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jul 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Taraasian Drugs?
Board Members(11)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhupendra Marliwar  | Director | 29-Sep-2017 | Current |
| Bhushan Marliwar | Director | 19-Jul-2017 | Current |
| Bhraman Marliwar | Director | 19-Jul-2017 | Current |
| Archana Deshmukh | Director | 26-Feb-2019 | Current |
| Vaishali Lande | Director | 26-Feb-2019 | Current |
| Girish Marliwar | Director | 03-Aug-2019 | Current |
Financial Performance and Corporate Structure Insights of Taraasian Drugs.
Taraasian Drugs Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 10.85% decrease. The company also saw a substantial fall in profitability, with a 787.96% decrease in profit. The company's net worth observed a substantial decline by a decrease of 22.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Taraasian Drugs?
In 2022, Taraasian Drugs had a promoter holding of 87.85% and a public holding of 12.15%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Signity Pharmaceuticals Private LimitedActive 14 years 3 monthsBhupendra Marliwar is a mutual person
- Tara Lifescience Private LimitedActive 7 years 8 months
Bhupendra Marliwar, Bhushan Marliwar and 1 more are mutual person
- 5 Milligram Pharmaceuticals Private LimitedActive 1 year 6 months
Bhupendra Marliwar and Bhushan Marliwar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Taraasian Drugs?
Unlock and access historical data on people associated with Taraasian Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Taraasian Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Taraasian Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
